An observational study in Pediatric ALL and Healthy, sponsored by HemoSonics LLC. Terminated at 1 site in United States. Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.
Sponsored by HemoSonics LLC (part of Stago) · Observational
Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.
Single center observational study of the pediatric patient population (\< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the Quantra QPlus system.
2,121 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 492 are open to participants now.
This study's enrollment of 93 is below the median of 120 across 313 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →HemoSonics LLC is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
First submitted after HemoSonics LLC became part of Stago.
Counted across the registry records on this site, refreshed daily.
Pediatric patients with normal coagulation function who have been scheduled to undergo a procedure and blood sampling access has been established. All genders, racial and ethnic profiles will be described.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
Also known as: Point of Care test, Quantra
Reference range interval for measurement of clot time (CT) parameter
Reference range interval determined in this study will serve as the reference for CT results in this particular population
Time frame: Baseline, after access placement before any procedures
Reference range interval for measurement of clot time (CTH) parameter
Reference range interval determined in this study will serve as the reference for CTH results in this particular population
Time frame: Baseline, after access placement before any procedures
Reference range interval for measurement of clot stiffness (CS) parameter
Reference range interval determined in this study will serve as the reference for CS results in this particular population
Time frame: Baseline, after access placement before any procedures
Reference range interval for measurement of Fibrinogen Contribution to clot stiffness (FCS) parameter
Reference range interval determined in this study will serve as the reference for FCS results in this particular population
Time frame: Baseline, after access placement before any procedures
Reference range interval for measurement of Platelet Contribution to clot stiffness (PCS) parameter
Reference range interval determined in this study will serve as the reference for PCS results in this particular population
Time frame: Baseline, after access placement before any procedures
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →